Michael J McNeil1, Arif H Kamal2, Jean S Kutner3, Christine S Ritchie4, Amy P Abernethy2. 1. Center for Learning Health Care, Duke Clinical Research Institute, Durham, North Carolina, USA; Duke University School of Medicine, Durham, North Carolina, USA. 2. Center for Learning Health Care, Duke Clinical Research Institute, Durham, North Carolina, USA; Duke Cancer Institute, Duke University School of Medicine, Durham, North Carolina, USA; Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA. 3. Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA. Electronic address: Jean.Kutner@ucdenver.edu. 4. Division of Geriatrics, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Abstract
CONTEXT: Patients with advanced illness are prescribed multiple medications in the last year of life, intensifying the risk of negative consequences related to polypharmacy. OBJECTIVES: To describe the medication burden of patients near the end of life and identify potential areas for improvement in clinician prescribing practices. METHODS: This was a prespecified secondary analysis of data from a prospective trial. Eligible participants were adults with less than 12 months estimated prognosis taking a statin medication for primary prevention of cardiovascular disease. Participants were enrolled from 15 sites, randomized to continue or discontinue statin medications, and followed for up to a year. Concomitant medications were recorded at least monthly from study enrollment through death. Prescribed medications were categorized by class and subclass. Descriptive statistics were calculated. RESULTS:On average, participants (n = 244) were 74.3 years old (SD 11.5) and lived 264 days (SD 128); 47.5% of the patients had a primary diagnosis of malignant tumor. This population was exposed to medications across 51 classes, 192 subclasses, and 423 individual medications. Patients took an average of 11.5 (SD 5) medications at the time of enrollment and 10.7 (SD 5) medications at death or study termination. The five most common classes of medications prescribed near the end of life were antihypertensives, broncholytics/bronchodilators, laxatives, antidepressants, and gastric protection agents. CONCLUSION: There is a significant medication burden placed on patients with advanced illness. Although most medications were prescribed for supportive care, we observed a high prevalence of medications for managing non-life-threatening comorbidities.
RCT Entities:
CONTEXT: Patients with advanced illness are prescribed multiple medications in the last year of life, intensifying the risk of negative consequences related to polypharmacy. OBJECTIVES: To describe the medication burden of patients near the end of life and identify potential areas for improvement in clinician prescribing practices. METHODS: This was a prespecified secondary analysis of data from a prospective trial. Eligible participants were adults with less than 12 months estimated prognosis taking a statin medication for primary prevention of cardiovascular disease. Participants were enrolled from 15 sites, randomized to continue or discontinue statin medications, and followed for up to a year. Concomitant medications were recorded at least monthly from study enrollment through death. Prescribed medications were categorized by class and subclass. Descriptive statistics were calculated. RESULTS: On average, participants (n = 244) were 74.3 years old (SD 11.5) and lived 264 days (SD 128); 47.5% of the patients had a primary diagnosis of malignant tumor. This population was exposed to medications across 51 classes, 192 subclasses, and 423 individual medications. Patients took an average of 11.5 (SD 5) medications at the time of enrollment and 10.7 (SD 5) medications at death or study termination. The five most common classes of medications prescribed near the end of life were antihypertensives, broncholytics/bronchodilators, laxatives, antidepressants, and gastric protection agents. CONCLUSION: There is a significant medication burden placed on patients with advanced illness. Although most medications were prescribed for supportive care, we observed a high prevalence of medications for managing non-life-threatening comorbidities.
Authors: Amy P Abernethy; Noreen M Aziz; Ethan Basch; Janet Bull; Charles S Cleeland; David C Currow; Diane Fairclough; Laura Hanson; Joshua Hauser; Danielle Ko; Linda Lloyd; R Sean Morrison; Shirley Otis-Green; Steve Pantilat; Russell K Portenoy; Christine Ritchie; Graeme Rocker; Jane L Wheeler; S Yousuf Zafar; Jean S Kutner Journal: J Palliat Med Date: 2010-11-24 Impact factor: 2.947
Authors: A Wilcock; J Thomas; J Frisby; M Webster; V Keeley; G Finn; K Fossey; B Wee; J Beale; M S Lennard Journal: Br J Clin Pharmacol Date: 2005-09 Impact factor: 4.335
Authors: David C Currow; James P Stevenson; Amy P Abernethy; John Plummer; Tania M Shelby-James Journal: J Am Geriatr Soc Date: 2007-04 Impact factor: 5.562
Authors: Dima M Qato; G Caleb Alexander; Rena M Conti; Michael Johnson; Phil Schumm; Stacy Tessler Lindau Journal: JAMA Date: 2008-12-24 Impact factor: 56.272
Authors: Yael Schenker; Seo Young Park; Kwonho Jeong; Jennifer Pruskowski; Dio Kavalieratos; Judith Resick; Amy Abernethy; Jean S Kutner Journal: J Gen Intern Med Date: 2019-02-04 Impact factor: 5.128
Authors: Michelle Vu; Florentina E Sileanu; Sherrie L Aspinall; Joshua D Niznik; Sydney P Springer; Maria K Mor; Xinhua Zhao; Mary Ersek; Joseph T Hanlon; Walid F Gellad; Loren J Schleiden; Joshua M Thorpe; Carolyn T Thorpe Journal: J Am Med Dir Assoc Date: 2020-07-25 Impact factor: 4.669
Authors: Patrick M Zueger; Holly M Holmes; Gregory S Calip; Dima M Qato; A Simon Pickard; Todd A Lee Journal: J Gen Intern Med Date: 2019-07-25 Impact factor: 6.473